| FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits | Ben Fidler | 01/30/17 | San Francisco |
| ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More | Ben Fidler | 12/06/16 | National |
| As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO | Ben Fidler | 11/14/14 | San Francisco |
| What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure | Stewart Lyman | 10/07/14 | Seattle |
| How a Little Serendipity Led Acceleron to a Crippling Blood Disease | Ben Fidler | 07/17/14 | Boston |
| Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race | Ben Fidler | 06/09/14 | Boston |
| Assigning Credit and Blame to Biopharma R&D Chiefs | Stewart Lyman | 05/29/13 | Seattle |
| Has The Pendulum Swung Too Far in Favor of Rare Diseases? | Stewart Lyman | 03/14/13 | Seattle |
| Rescuing Patent-Less Proteins from the Drug Development Dustbin | Stewart Lyman | 11/06/12 | Seattle |
| Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Luke Timmerman | 03/27/12 | San Francisco |
| Affymax Prepares to Mount Challenge to Amgen Anemia Drug Monopoly | Luke Timmerman | 01/25/12 | San Francisco |
| Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs | Luke Timmerman | 12/19/11 | National |
| Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny | Luke Timmerman | 11/17/11 | San Francisco |
| Columbia University’s Tech Transfer Guru, Orin Herskowitz, on Turning IT, Biotech, and Cleantech Ideas Into Businesses | Arlene Weintraub | 04/04/11 | New York |
| Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug | Luke Timmerman | 01/06/11 | San Francisco |
| AlloCure, With Stem Cell Therapy for Kidney Failure, Arrives in New England with New CEO | Luke Timmerman | 07/06/10 | Boston |
| GlycoFi Figures Heavily into Drug Giant Merck’s Follow-on Biologics Plans | Ryan McBride | 04/23/09 | Boston |
| Amgen Scientist, After 13-Year Push, Sees Bone Cancer Work Paying Dividends | Luke Timmerman | 10/29/08 | Seattle |
| CMC Icos Sees Expanding Markets for Biotech Drugs With New Factory | Luke Timmerman | 10/14/08 | Seattle |
| Amgen’s Dmab Cuts Fracture Risk for Osteoporosis Patients, Just What Investors Wanted to See | Luke Timmerman | 09/16/08 | Seattle |
| Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs | Luke Timmerman | 08/07/08 | National |
